Compare BridgeBio Pharma Inc (BBIO) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Zscaler Inc — how do they compare? BridgeBio Pharma Inc trades at $84.48 (market cap $16.36B), while Zscaler Inc trades at $176.5 (market cap $28.87B). The key difference: Zscaler Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | ZS | |
|---|---|---|
Market Cap | $16.36B | $28.87B |
Sector | Health | Technology |
52-Week High | $90.17 | $336.27 |
52-Week Low | $47.29 | $118.05 |
Enterprise Value | $18.14B | $27.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.
The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.
Zscaler (ZS) trades at $176.11, showing modest daily movement. The stock exhibits a bullish technical trend with strong analyst support, evidenced by 42 buy ratings and a consensus price target of $191.81. Recent earnings consistently beat expectations, with Q1 2026 EPS of $1.08 surpassing the $1.01 forecast. Revenue growth is robust, increasing from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net income margin of -2.44%.
The outlook is positive due to strong revenue growth, leadership in cloud security, and bullish analyst sentiment. Key risks include persistent unprofitability, high valuation multiples like a P/S of 8.94, and competitive pressures in the cybersecurity sector. The upcoming Q2 2026 earnings report on September 3, 2026, will be critical for validating growth trajectory and investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
